Rituximab Maintenance Delays Need for More Aggressive Treatment in Follicular Lymphoma

Researchers sponsored in part by Cancer Research UK explored whether patients with advanced-stage, low tumor burden follicular lymphoma could benefit from rituximab.

Rituximab has the potential to delay the need for chemotherapy or radiotherapy in a more proactive manner as compared to the current protocol of watchful waiting. They also explored whether this strategy had an effect on quality of life.

The study recruited 379 patients from 118 centers in the U.K., Australia, New Zealand, Turkey, and Poland. They were randomly assigned either to watchful waiting or maintenance rituximab.

Initially, 84 patients were recruited to rituximab induction, in which they received rituximsb once a week for four weeks but the arm was closed early.

Investigators found a significant difference in the time to start of new treatment at three years:

  • 46 percent of patients in the watchful waiting group did not need treatment at three years
  • 88 percent in the maintenance rituximab group did not need treatment at three years
  • 78 percent in the rituximab induction group did not need treatment at three years

Rituximab should be considered as a treatment option

Compared with the watchful waiting group, patients in the maintenance rituximab group had significant improvements in the Mental Adjustment to Cancer scale score, and Illness Coping Style score between baseline and month 7. Patients in the rituximab induction group did not show improvements in their quality of life compared with the watchful waiting group.

There were 18 serious adverse events reported in the rituximab groups (four in the rituximab induction group and 14 in the maintenance rituximab group), 12 of which were grade 3 or 4 (five infections, three allergic reactions, and four cases of neutropenia), all of which fully resolved.

Researchers concluded that rituximab monotherapy should be considered as a treatment option for patients with asymptomatic, advanced-stage, low tumor burden follicular lymphoma.

Source: The Lancet

More Articles

More Articles

This entry looks at Non Hodgkin's Lymphoma in the lungs, clinically known as pulmonary lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

The Erythrocyte Sedimentation Rate (ESR - sometimes called sed rate or sedimentation rate) is a nonspecific screening test for various...

Blood counts can be used to identify disease and monitor patient health during cancer treatments. Though these tests cannot diagnose lymphoma on...

MALT lymphoma is a rare B-cell non-Hodgkin's lymphoma that typically runs an indolent or slow-growing clinical...

Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of...

After some of the dust has settled, the thoughts of many new lymphoma patients turn to diet and nutrition. They want to know if, in the past,...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

In a perfect world, every case of cancer would respond to, and be cured by first-line therapy. Unfortunately, it is not often the case. This is...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

In 1964, researchers at the National Cancer Institute developed the first combination chemotherapy that cured a...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...